Solution for oral administration.
100 ml in bottles of OS brand glass or stained glass, sealed with caps with the first opening control, with a dropper made of polyethylene. Each bottle, together with instructions for medical use, is placed in a pack of cardboard.
Other antitussive drugs.
ATX code: R05DB
Pharmacological properties of
It has been experimentally shown that the components of the drug modify the activity of the ligand-receptor interaction of endogenous regulators with antibodies to morphine (a component of the drug) modify the activity of the ligand-receptor interaction of endogenous regulators of antigen regulators – with H1 histamine receptors for anti-bradykinin antibodies – with bradykinin receptors with the combined use of components leads to increased antitussive effect.
In addition to the antitussive effect, the complex drug due to its constituents has anti-inflammatory, decongestant, antiallergic, antispasmodic (antibodies to histamine, antibodies to bradykinin) and analgesic effect (antibodies to morphine).
The complex drug Rengalin, by modifying the histamine-dependent activation of the H1 receptors of the bradykinin-dependent activation of B1 and B2 receptors, selectively reduces the excitability of the cough center of the medulla oblongata, inhibits the central links of the cough reflex. Inhibiting the centers of pain sensitivity in the thalamus, it blocks the transmission of pain impulses to the cerebral cortex. It inhibits the flow of pain impulses from the periphery due to a decrease in the release of tissue and plasma algogens (histamine, bradykinin, prostaglandins, etc.). Unlike narcotic analgesics, it does not cause respiratory depression, drug dependence, does not have narcogenic and hypnotic effects.
Facilitates the manifestations of acute pharyngitis, laryngitis and bronchitis, reducing bronchospasm. Relieves systemic and local symptoms of allergic reactions due to the effect on the synthesis and release of histamine and bradykinin from mast cells.
The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow us to evaluate the content of the active components of Rengalin in biological fluids, organs and tissues, which makes it impossible to study pharmacokinetics.
Acute and chronic respiratory diseases accompanied by cough and bronchospasm. Productive and unproductive cough for influenza and SARS, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis and other infectious and inflammatory and allergic diseases of the upper and lower respiratory tract.
Use during pregnancy and lactation
The safety of Rengalin in pregnant women and during breastfeeding has not been studied. During pregnancy and during breastfeeding, the drug is used only if the intended benefit to the mother outweighs the potential risk to the fetus and the baby. The benefit / risk ratio is determined by the attending physician.
For diseases accompanied by dry (unproductive) cough, it contributes to its transition to a wet (productive) cough.
If necessary, a combination with mucolytics is possible.
Patients with diabetes should remember that each teaspoon (5 ml) of the drug contains 0.3 g of maltitol, which corresponds to 0.02 bread units (XE). Maltitol metabolism requires insulin, although due to the slow hydrolysis and absorption in the gastrointestinal tract, the need for insulin is small. The energy value of maltitol is 10 kJ or 2.4 kcal / g, which is significantly less than that of sucrose. The energy value of one teaspoon of the drug is approximately 5.7 kJ (1.37 kcal).
Effect on ability to drive vehicles,
mechanisms Not studied.
Composition (per 100 ml)
oral solution Active Substances: Antibodies to bradykinin, affinity-purified 0.12 g *
Antibodies to histamine affi purely purified 0.12 g *
Antibodies to morphine affinity purified 0.12 g *
* are administered as a mixture of three active aqueous dilutions of a substance diluted 10012, 10030, 10050 times, respectively.
Excipients: hypromellose 1.0 g, maltitol 6.0 g, glycerol 3.0 g, potassium sorbate 0.165 g, anhydrous citric acid 0.02 g, purified water to 100 ml.
Dosage and Administration
Inside. At one time – 1-2 teaspoons (5-10 ml) – out of meals. It is advisable to keep the solution in the mouth before swallowing for the maximum effect of the drug.
Use 1-2 teaspoons 3 times a day. Depending on the severity of the condition in the first three days, the frequency of admission can be increased up to 4-6 times a day.
The duration of therapy depends on the severity of the disease and is determined by the attending physician.
Possible reactions of increased individual sensitivity to the components of the drug. If these side effects are exacerbated, or if you notice any other side effects not listed in the instructions, inform your doctor.
During clinical trials no data were obtained on the interaction of Rengalin with drugs used as concomitant therapy.
In case of accidental overdose, dyspeptic symptoms (nausea, vomiting, diarrhea) due to excipients (maltitol, glycerol) included in the preparation are possible.
Treatment is symptomatic.
At a temperature not exceeding 25 ° C. Keep out of reach of children. Do not freeze.
Solution for pryema inside